Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$7.42 - $10.54 $1,513 - $2,150
-204 Reduced 0.53%
38,149 $301,000
Q1 2024

May 14, 2024

BUY
$7.15 - $10.84 $20,856 - $31,620
2,917 Added 8.23%
38,353 $357,000
Q4 2023

Feb 14, 2024

SELL
$6.28 - $8.81 $15,473 - $21,707
-2,464 Reduced 6.5%
35,436 $299,000
Q3 2023

Nov 14, 2023

BUY
$7.55 - $11.25 $286,145 - $426,375
37,900 New
37,900 $293,000
Q2 2021

Aug 11, 2021

SELL
$3.94 - $5.44 $267,061 - $368,734
-67,782 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$4.61 - $9.04 $3,508 - $6,879
761 Added 1.14%
67,782 $319,000
Q4 2020

Feb 03, 2021

BUY
$7.15 - $12.28 $137,930 - $236,893
19,291 Added 40.42%
67,021 $479,000
Q3 2020

Nov 04, 2020

SELL
$10.01 - $13.75 $29,689 - $40,782
-2,966 Reduced 5.85%
47,730 $509,000
Q2 2020

Aug 05, 2020

SELL
$8.05 - $14.21 $134,443 - $237,321
-16,701 Reduced 24.78%
50,696 $640,000
Q1 2020

May 06, 2020

SELL
$6.8 - $14.66 $53,468 - $115,271
-7,863 Reduced 10.45%
67,397 $617,000
Q4 2019

Feb 07, 2020

BUY
$12.82 - $16.85 $20,204 - $26,555
1,576 Added 2.14%
75,260 $1.05 Million
Q3 2019

Nov 04, 2019

SELL
$16.31 - $28.29 $55,584 - $96,412
-3,408 Reduced 4.42%
73,684 $1.27 Million
Q2 2019

Aug 07, 2019

SELL
$19.18 - $27.88 $29,633 - $43,074
-1,545 Reduced 1.96%
77,092 $2.1 Million
Q1 2019

May 01, 2019

BUY
$8.0 - $19.66 $27,152 - $66,726
3,394 Added 4.51%
78,637 $1.51 Million
Q4 2018

Feb 04, 2019

BUY
$8.59 - $18.05 $153,279 - $322,084
17,844 Added 31.09%
75,243 $707,000
Q3 2018

Oct 25, 2018

BUY
$17.11 - $21.74 $179,637 - $228,248
10,499 Added 22.39%
57,399 $1.09 Million
Q2 2018

Aug 02, 2018

BUY
$16.76 - $23.92 $786,044 - $1.12 Million
46,900 New
46,900 $916,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $223M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.